Fact.MR – A Market Research and Competitive Intelligence Provider: As per the latest study by Fact.MR, the combined immune deficiency market will grow at a healthy rate through 2021 and years ahead.
Increasing Incidence of Combined Immune Deficiency Diseases Set to Boost Gene Therapy Demand across Hospitals
Market research conducted by Fact.MR on the combined immune deficiency (CID) market offers comprehensive view on chief growth drivers and restrains influencing the market’s growth trajectory through 2031. The report presents compelling case studies and information about CID demand outlook in terms of therapy type, diseases type, and end user. Growth strategies adopted by top market players to improve sales also are discussed in this report.
Fact.MR – A Market Research and Competitive Intelligence Provider: As per the latest study by Fact.MR, the combined immune deficiency (CID) market will grow at a healthy rate through 2021 and years ahead. Increasing cases of combined immune deficiency (CID) disorders along with consumer spending on advanced healthcare will fuel the demand for CID treatments.
COVID-19 pandemic had a significant impact on the CID market. Patients suffering from immunity ailments are more susceptible to developing infectious diseases and the novel coronavirus weakened the immune system thus leading to spike in number of CID patients, seeking consistent medical help. High risk of morbidity and fatality of CID patients due to COVID-19 has fueled the demand for treatments during the ongoing pandemic crisis.
The American Academy of Pediatrics reported that 1 in 2000 children and 1 in 600 households get diagnosed with primary immune deficiency every year. Rise in research and development (R&D) activities undertaken to identify faulty gene that might cause CID, will accelerate gene sequencing and other drug development procedures. This will drive the market growth during the forecast period.
Genetic mutation tops the list of leading causes of immunity defects in terms of cell mediated and related parameters. With genetic mutation and defect induced CID ailments now affecting respiratory systems, gastrointestinal tracts, nervous systems, urinary tracts, and sensory organs, the demand for combined immune deficiency treatments will grow exponentially in the future.
A wide array of options, including stem cell transplants, antibiotic therapy, and immunoglobulin replacement therapy are available to help manage long term symptoms of CID. Increasing investments towards treatment research will therefore support the market growth throughout the forecast period.
“Researches undertaken to identify genetic defects will influence the combined immune deficiency treatment development. Leading research institutes are focusing on studying these immunity disorders on genetic level to identify the causes and trigger points of various diseases. Investment in such projects will boost the market growth in upcoming decade”, said a Fact.MR analyst.
For More Information On How To Improve Your Combined Immune Deficiency (CID) Market Footprint, Request A Sample Here
https://www.factmr.com/connectus/sample?flag=S&rep_id=5276
Key Takeaways from Combined immune deficiency (CID) Market Research Report:
- The U.S. is forecast to lead the North America combined immune deficiency market owing to increasing cases of immunity ailments among toddlers along with presence of modern healthcare infrastructure in the country.
- Rising government investment towards research and development of affordable gene therapy and other immunity disorder treatments is expected to make India a lucrative market over the forecast period.
- China is expected to exhibit tremendous growth in combined immune deficiency market owing to increasing research and development activities to improve medical and healthcare system in the country.
- Gene therapy treatment will hold maximum market share due to increasing research investment and promising results from ongoing clinical trials.
- Wide of treatment options offered by antibody deficiency treatment will bolster the market growth over the assessment period.
Growth Drivers:
- Increasing cases of combined immune deficiencies (CID) across the globe especially among children and infants will drive demand for CID treatments over the forecast period.
- Increasing government and private funding for development of novel treatments for combined immune deficiencies will augment the market growth.
- Adoption of modern technology in gene therapy and therapeutic research for developing CID treatment will positively influence the market growth.
Key Restraints:
- Lack of awareness among consumers regarding combined immune deficiency disorders especially in developing countries will hinder the market growth.
- Shortage of funding and unavailability of proper diagnostic facilities will hamper the adoption of combined immune deficiency treatments.
- High cost of gene therapy for treating combined immune deficiency and strict regulatory policies for treatment approval will restrict the market growth.
Ask Your Combined Immune Deficiency (CID) Market Related Questions & Get Customized Reports
https://www.factmr.com/connectus/sample?flag=RC&rep_id=5276
Competitive Landscape
According to Fact.MR, Baxter International Inc., LFB S.A., Biotest AG, Shire Plc, Grifols S.A. are identified as top market players operating in combined immune deficiency market. They collectively account for maximum market share as of 2021. Market players are employing organic and inorganic growth strategies to expand their foothold in this competitive market.
They are investing heavily towards product research and development along with collaborating with other industries to pool resources and expertise and strengthen their product portfolio for personalized treatments.
For instance, Genome institute collaborated with University of California, University of Berkeley, and UC San Francisco for development of CRISPR test. In March 2021, they received the Food and Drug Administration (FDA) approval for their CRISPR test to rectify genetic defects related with sickle cell disease.
Bioverge launched its equity crowd-funding platform called “Bioverge Portal” in April 2021. This platform is designed to assist professional investors in investing into treatments from private healthcare startups.
In November 2020, Mustang Bio Inc. signed a joint agreement with Minaris Regenerative medicine to share technology for research on MB-107 lentiviral gene therapy for X-linked severe combined immunodeficiency and GMP production.
Key players operating in the combined immune deficiency (CID) market are
- LFB SA
- Shire plc
- Kedrion Biopharma Inc
- CSL Behring
- Octapharma
- China Biologic Products Holdings, Inc
- Sanquin,
- Grifols, S.A
- Biotest AG,
- Baxter International Inc.
More Insights on the combined immune deficiency (CID) Market:
Fact MR provides an unbiased analysis of the combined immune deficiency (CID) market, presenting historical demand data (2020-2030) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global combined immune deficiency (CID) market with a detailed segmentation on the basis of:
Disease Type
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
Therapy Type
- Immunoglobulin Replacement Therapy
- Bone marrow transplant
- Stem cell transplant
- Lung transplant
- Gene therapy
- Others
End User
- Hospitals
- Ambulatory surgical care
- Research and development institutes
Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Key Questions Covered In the Combined Immune Deficiency (CID) Market Report
- The report offers insight into combined immune deficiency (CID) demand outlook for 2021-2031
- The market study also highlights projected sales growth for combined immune deficiency (CID) market between 2021 and 2031
- Combined immune deficiency (CID) market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Combined immune deficiency (CID) market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others.
Explore Fact.MR’s Coverage on the Healthcare Domain
Immunoglobulins Market - The high prevalence of neurological, immunological, and other disorders, high adoption of IVIG products, significant reimbursement coverage, and the presence of major market players all contribute to growth in North America. The expanding healthcare market, untapped potential, and acceptance of immunoglobulin products in developing countries, as well as an increasing geriatric population, are the key drivers bolstering Asia-Pacific market growth.
Immunoassay Market – Market for immunoassay is expected to expand in the future, driven by increased testing adoption against the backdrop of rising chronic and infectious disease prevalence. Furthermore, the coronavirus pandemic is expected to provide additional stimulus to the immunoassay testing market. The introduction of integrated systems, in conjunction with the development of ultrasensitive analyzer systems, is expected to boost prospects for the global immunoassay market.
Immunodermatology Market - Pores and skin conditions are very different health problems that affect many people across the country; when combined, they outnumber conditions such as obesity, high blood pressure, and disease. The growing number of older people, increased disposable income, increased health insurance, and the growing need for early diagnosis of skin conditions will all contribute to an increase in immunodermatology market size.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR